# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0002007191-25-000071
Filing Date
2025-10-14
Accepted
2025-10-14 08:36:04
Documents
7
Period of Report
2025-10-14

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS | q3results6k.htm | 6-K | 11044
2 | EX-99.1 | prq3.htm | EX-99.1 | 450
3 |  | prq31.jpg | GRAPHIC | 343424
4 |  | prq32.jpg | GRAPHIC | 340682
5 |  | prq33.jpg | GRAPHIC | 307688
6 |  | prq34.jpg | GRAPHIC | 380522
7 |  | prq35.jpg | GRAPHIC | 311696
| Complete submission text file | 0002007191-25-000071.txt |  | 2331919

Mailing Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051
Business Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855
Telix Pharmaceuticals Ltd (Filer) CIK: 0002007191 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-42128 | Film No.: 251389913
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)